Glenmark Pharmaceuticals launches TEVIMBRA in India

TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)

BASF opens new GMP Solution Center in US

BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America

AbbVie announces new data demonstrating Atogepant achieves superiority in Phase 3 study

TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month

Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx

Biogen initiates Phase 3 pediatric study of Omaveloxolone for treatment of Friedreich Ataxia

BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population

UFlex introduces FSSAI compliant single-pellet solution for food packaging

UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials

Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025

Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression

Bristol Myers Squibb announces positive results from Phase 3 Poetyk PsA-1 and PsA-2 trials of deucravacitinib in psoriatic arthritis

Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies

Globally, BRUKINSA is approved in more than 70 countries